GlaxoSmithKline plc (LON:GSK) had its target price reduced by investment analysts at Liberum Capital from GBX 1,900 ($25.20) to GBX 1,760 ($23.35) in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock. Liberum Capital’s price objective would suggest a potential upside of 15.52% from the company’s previous close.

GSK has been the topic of a number of other reports. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 28th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Monday, July 24th. S&P Global set a GBX 1,500 ($19.90) price objective on GlaxoSmithKline plc and gave the company a “sell” rating in a research report on Wednesday, July 26th. Jefferies Group LLC lowered their price objective on GlaxoSmithKline plc from GBX 1,750 ($23.21) to GBX 1,675 ($22.22) and set a “buy” rating on the stock in a research report on Monday, September 18th. Finally, Credit Suisse Group AG lowered their price objective on GlaxoSmithKline plc from GBX 1,775 ($23.54) to GBX 1,725 ($22.88) and set a “neutral” rating on the stock in a research report on Wednesday, September 6th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have given a buy rating to the company. GlaxoSmithKline plc has a consensus rating of “Hold” and an average target price of GBX 1,691.86 ($22.44).

GlaxoSmithKline plc (GSK) opened at 1528.00 on Wednesday. The firm has a 50-day moving average of GBX 1,497.17 and a 200-day moving average of GBX 1,591.53. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,745.56. The firm’s market cap is GBX 74.69 billion.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/liberum-capital-lowers-glaxosmithkline-plc-gsk-price-target-to-gbx-1760/1611937.html.

In other news, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were acquired at an average price of GBX 1,599 ($21.21) per share, with a total value of £36,249.33 ($48,082.41). Also, insider Patrick Vallance purchased 861 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were purchased at an average cost of GBX 1,618 ($21.46) per share, for a total transaction of £13,930.98 ($18,478.55). Insiders have bought 3,152 shares of company stock worth $5,055,023 in the last ninety days.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.